Cao Aie

Chief Physician

Surgical treatment of gynecological benign and malignant tumors such as cervical cancer, endometrial cancer, ovarian cancer, uterine fibroids, ovarian cancer, endometriosis, uterine prolapse, uterine adhesions and other diseases, has rich experience in chemotherapy, targeted therapy and immunotherapy of gynecological malignant tumors such as cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer, etc. has performed over 10,000 laparotomy and minimally invasive laparoscopic, hysteroscopic and vaginal surgeries.

Introduction of the expert

Director of Gynecology, chief Physician. From Hunan Province, graduated from Nanchang University, has been engaged in obstetrics and gynecology clinical work for more than 30 years after graduation, has gone to Xiangya Hospital of Central South University, Obstetrics and Gynecology Department of Peking Union Medical College Hospital, Wayne State University in the United States to study for further education.

Medical specialty

Mainly good at: Surgical treatment of gynecological benign and malignant tumors such as cervical cancer, endometrial cancer, ovarian cancer, uterine fibroids, ovarian cancer, endometriosis, uterine prolapse, uterine adhesions and other diseases, has rich experience in chemotherapy, targeted therapy and immunotherapy of gynecological malignant tumors such as cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer, etc. has performed over 10,000 laparotomy and minimally invasive laparoscopic, hysteroscopic and vaginal surgeries.

Direction of scientific research

Experimental study on fertility preservation operation for ovarian epithelial carcinoma

Academic position

1. Standing member of the 4th Committee of Minimally Invasive Gynecological Branch of Hainan Medical Association

2. Member of the Medical Genetics Association of Hainan Medical Association

3. Member of Maternal-fetal Medical Association, Obstetrics and Gynecology Professional Committee of Hainan Medical Association

Papers and works

1. Expression and Clinical Significance of Ubiquitin-specific Protease I and Karyopherin a-2 in Endometriosis Patients, China Journal of Eugenics and Genetics, Volume 30, 2022

2. Study on the Mechanism of Regulation of Proliferation and Apoptosis of Cervical Cancer Cells by Targeting mid-506-5P with Inc RNA FOXD2-ASI", Chinese Journal of Cancer Biotherapy, Vol. 26, Issue 10

3. 2020 Research Project of Hainan Provincial Health Department (in progress): Study on the Application of Low Molecular Weight Heparin Sodium in Patients with Recurrent Abortion

4. Also participated in the ongoing national multicenter clinical studies, including Multicenter Screening and Early Diagnosis of Endometrial Cancer in High Risk Groups and Study of Cervical Cytology DNA Early Basification for Endometrial Cancer Screening.